Advanced metastatic
melanoma, one of the most aggressive
malignancies, is currently without reliable
therapy. Therefore, new
therapies are urgently needed.
Mangiferin is a naturally occurring glucosylxanthone and exerts many beneficial biological activities. However, the effect of
mangiferin on
metastasis and
tumor growth of metastatic
melanoma remains unclear. In this study, we evaluated the effect of
mangiferin on
metastasis and
tumor growth in a mouse metastatic
melanoma model. We found that
mangiferin inhibited spontaneous
metastasis and
tumor growth. Furthermore,
mangiferin suppressed the nuclear translocation of
nuclear factor kappa B (NF-κB) and expression of phosphorylated NF-κB-inducing
kinase (NIK), inhibitor of kappa B
kinase (IKK), and inhibitor of kappa B (IκB) and increases the expression of IκB
protein in vivo. In addition, we found that
mangiferin inhibited the expression of
matrix metalloproteinases (
MMPs) and very late
antigens (VLAs) in vivo.
Mangiferin treatment also increased the expression of cleaved
caspase-3, cleaved
Poly ADP ribose polymerase-1 (PARP-1), p53 upregulated modulator of apoptosis (PUMA), p53, and phosphorylated p53
proteins, and decreased the expression of
Survivin and Bcl-associated X (Bcl-xL)
proteins in vivo. These results indicate that
mangiferin selectivity suppresses the NF-κB pathway via inhibition of NIK activation, thereby inhibiting
metastasis and
tumor growth. Importantly, the number of reported NIK selective inhibitors is limited. Taken together, our data suggest that
mangiferin may be a potential therapeutic agent with a new mechanism of targeting NIK for the treatment of metastatic
melanoma.